Exogenus Therapeutics is proud to announce a new research collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles as therapeutic tools for regenerative medicine. This joint effort led by Boehringer Ingelheim’s Research Beyond Borders (RBB) Unit focuses on preclinical testing of Exogenus Therapeutics’s lead candidate, Exo101, in various regenerative medicine indications.

Exo101 is enriched in extracellular vesicles secreted by preconditioned umbilical cord blood mononuclear cells, which exhibit immunomodulatory and regenerative properties1,2 and a safe toxicological profile3demonstrated in preclinical studies.

Joana Correia, CEO of Exogenus Therapeutics, emphasized “We are delighted to partner with Boehringer Ingelheim in this endeavor, in the hope of unlocking new options for more patients with unmet needs. Our previous work with Exo101 demonstrates a contextdependent multifactorial mechanism of action, which supports its use for the treatment of different diseases. Exploring natural extracellular vesicles as therapeutic alternatives is an innovative approach that has the potential to change the current paradigm of medicine, by inducing the intrinsic potential for organ regeneration and to accelerate the reach of exosomes to patients in need.


1.     Cardoso RMS, Rodrigues SC, Gomes CF, et al. Development of an Optimized and Scalable Method for Isolation of Umbilical Cord Blood-Derived Small Extracellular Vesicles for Future Clinical Use. Stem Cells Transl Med. 2021;10(6):910921. doi:https://doi.org/10.1002/sctm.200376

2.     Rodrigues SC, Cardoso RMS, Freire PC, et al. Immunomodulatory Properties of Umbilical Cord BloodDerived Small Extracellular Vesicles and Their Therapeutic Potential for Inflammatory Skin Disorders. Int J Mol Sci. 2021;22(18):9797. doi:10.3390/ijms22189797

3.     Rodrigues SC, Cardoso RMS, Gomes CF, et al. Toxicological Profile of Umbilical Cord BloodDerived Small Extracellular Vesicles. Membranes (Basel). 2021;11(9):647. doi:10.3390/membranes11090647